EUVIMED · CrossrefZeitschrift
Journal of Cystic Fibrosis
ISSN 1569-1993 · Elsevier BV
Neueste Artikel
Continued burden of nontuberculous mycobacteria in the screened subpopulations of people with cystic fibrosis receiving CFTR modulator therapy
Medication burden among adults with cystic fibrosis prescribed CFTR Modulators: a cross-sectional survey
Beyond lung function: the changing landscape of cystic fibrosis-related diabetes
News article
Bacteriophage associated liver injury in a person with cystic fibrosis and prior liver transplantation
Current knowledge, key gaps, and opportunities for future research on high-impact, modifiable lifestyle behaviors to promote healthy aging in adults with cystic fibrosis in the era of modulator therapy
Airway microbial-inflammatory endotypes are associated with disease severity and predicted survival in cystic fibrosis
Vanzacaftor/tezacaftor/deutivacaftor partially restores CFTR function of the L467F;F508del complex allele in primary nasal epithelial cells
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study
Changes in chronic therapies for cystic fibrosis following initiation of CFTR modulators: A UK retrospective cohort study 2009 - 2023
Persistence of large P. aeruginosa aggregates despite reduced airway burden in people with cystic fibrosis on CFTR modulator therapy
In Vitro Responsiveness of 417 CFTR Variants to Vanzacaftor/Tezacaftor/Ivacaftor
A functional comparison of readthrough agent ELX-02 across a wide range of nonsense CFTR variants
Intestinal organoids as a platform for functional evaluation of ASO-mediated splicing modulation in cystic fibrosis
Current drug hypersensitivity challenges facing patients with cystic fibrosis
Prenatal initiation of elexacaftor/tezacaftor/ivacaftor via carrier mother prevents congenital bilateral absence of vas deferens in a male infant with cystic fibrosis
Consensus-based guidance for the nutritional management of children with cystic fibrosis on ELEXACAFTOR/TEZACAFTOR/IVACAFTOR
Outcomes of SARS-CoV-2 infection post-solid organ transplantation in the cystic fibrosis population
Impact of Elexacaftor-Tezacaftor-Ivacaftor on fungal colonisation in children and adolescents with cystic fibrosis
Clinical, functional and therapeutic evaluation of CFTR variant I507del
Discussing the potential health impacts of carrying a single CF-causing CFTR mutation during consult with people with CF who are planning a pregnancy
The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France
CFTR knock-out mice exhibit impaired renal compensation to dietary NaCl depletion
Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey
Density fluctuations of Burkholderia and Achromobacter in cystic fibrosis sputum
Microbiological outcomes associated with Burkholderia species in people with cystic fibrosis receiving CFTR modulator therapy
Safety of inhaled levofloxacin in people with cystic fibrosis: Data from UK and German Registries
Apical hyperosmotic challenge upregulates aquaporin-3 in human airway epithelia
Treatment with elexacaftor/tezacaftor/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis
Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis
EUVIMED